Description
The theorist proposed biased PDGFR-β agonism targeting PI3K/Akt while avoiding MAPK activation, but the specific molecular mechanisms for achieving this selectivity remain undefined. This represents a critical druggability challenge for pericyte-targeted therapies.
Source: Debate session sess_SDA-2026-04-01-gap-v2-ee5a5023 (Analysis: SDA-2026-04-01-gap-v2-ee5a5023)